John R. Richert

Georgetown University Medical Center, Washington, DC, United States 
Neuroscience Biology, Molecular Biology
"John Richert"
Mean distance: 21373.2
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Bove R, White CC, Giovannoni G, et al. (2015) Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis. Neurology® Neuroimmunology & Neuroinflammation. 2: e162
Teunissen C, Menge T, Altintas A, et al. (2013) Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1802-9
Bushnell SE, Zhao Z, Stebbins CC, et al. (2012) Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology. 79: 531-7
Wang YC, Sandrock A, Richert JR, et al. (2011) Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab. Neurology Research International. 2011: 195831
Mehta LR, Schwid SR, Arnold DL, et al. (2009) Proof of concept studies for tissue-protective agents in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 542-6
Miller DH, Weinshenker BG, Filippi M, et al. (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 1157-74
Polman CH, Reingold SC, Barkhof F, et al. (2008) Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 70: 1134-40
Castro HJ, Mendez-Lnocencio JI, Omidvar B, et al. (2005) A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis. Allergy and Asthma Proceedings : the Official Journal of Regional and State Allergy Societies. 26: 470-6
Herndon RM, Rudick RA, Munschauer FE, et al. (2005) Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 11: 409-19
Moran KM, Crusio RH, Chan CH, et al. (2004) Human transcription factor Sp3: genomic structure, identification of a processed pseudogene, and transcript analysis. Gene. 341: 235-47
See more...